



International
22q11.2 Foundation

Newsletter March 2025

Celebrating 22 Years!

*Always present.
Always supportive.
Always committed.*



In this newsletter...

- p. 2-5 – Walking Down the Memory Lane
- p. 6 – A Little History on 22q11.2 Deletion Syndrome
 - Adult Congenital Heart Disease (ACHD): A Walk Down Memory Lane
- p. 7 – 22q Differences and Inflammatory Profiles
- p. 8 – Immune Series Now Available
 - Clinical Recommendations for 22q11.2DS Now Available in 4 Languages
- p. 9 – 19th Annual Faces of Sunshine Calendar
- p. 10 – Did You Miss Our No Show Valentine's Ball?
 - 2025 Lighting Request Letter Now Available
- p. 11 – 22q at the Zoo – May 18th, 2025
- p. 12 – Upcoming Symposiums / Meeting / Gala
- p. 13 – Donate Now

The International 22q11.2 Foundation is celebrating an amazing milestone as we proudly commemorate the 22nd anniversary of our commitment to the global 22q community!

Since our inception in 2003, we have been dedicated to supporting families affected by chromosome 22q differences, beginning with the deletion, and expanding to the duplication - ensuring that no family faces 22q related challenges alone.

During this time, in partnership with our international family organization collaborators, we have worked tirelessly to raise awareness, striving to make 22q a household word, including via events such as 22q at the Zoo – Worldwide Awareness Day.

Leaning on our internationally recognized expert medical advisors, we have provided invaluable resources for healthcare providers and caregivers alike through our state-of-the-art 22q.org website. Likewise, we have supported scientific and family educational programming, given we are committed to keeping the 22q community informed about current research developments and clinical advances - all while fostering vital interpersonal connections.

As we celebrate this 22-year journey, we reflect on the progress we've made and the impact we've had on countless families, scientists, and healthcare providers. It has sure been hard work, but more than worth the enormous effort. We thank every single volunteer who has helped us along the way and those who have trusted us to be the “go to” place for everything 22q. Together, we will continue our mission – to improve the quality of life for individuals affected by 22q differences through family and professional partnerships. Here's to many more years of making a difference!

Walking Down The Memory Lane

Back in 2003, a diagnosis of 22q11.2 deletion syndrome was not well understood, and many parents struggled for information about their child's treatment, care, and long-term outcomes. Many of them shared a common bond: isolation and uncertainty.

That year, a small group of parents and a local professional decided they wanted to make a difference. While sitting around a kitchen table in suburban Philadelphia, the group brainstormed about how they might help those affected by 22q11.2DS. Shortly thereafter the group created **The International 22q11.2 Deletion Syndrome Foundation, Inc.** with these goals:

1. Improve detection;
2. Care for families;
3. Help raise awareness among clinicians, teachers, and the general public; and
4. Support research that would improve outcomes for affected individuals and their families.

2003 Founding board members

- Mark Abissi (Chair)
- Dottie Specht (Vice-Chair)
- Missy Disibio (Secretary)
- Wendy Rose (Treasurer)
- Donna McDonald-McGinn
- Mark Weinberg
- Carol Cavana

The foundation's first logo



In 2006, our Foundation unveiled the first **calendar fundraiser** with a 2007 calendar that showcased our loved ones. This tradition would continue for years to come. Here are the cover pages of the 2007 and 2008 calendars.



In 2008, our Foundation sponsored a booth at the [American Society of Human Genetics \(ASHG\) conference](#) in November in Philadelphia, PA, USA with a grant of \$4,000



In 2011, our Foundation contributed significant financial support to the [Dragonfly Forest Camp](#) to help provide a wonderful week of overnight summer camp dedicated exclusively to campers with 22q.



The organizing committee of the very first **22q at the Zoo** posing in Philadelphia Zoo on May 22, 2011. Donna McDonald-McGinn was the person who coined the event name "22q at the Zoo – Worldwide Awareness Day". See the history of the event [here](#).

Walking Down The Memory Lane (p. 2 of 4)



In 2011, medical specialists from multiple countries published the **first set of clinical practice guidelines** for the care of individuals affected by 22q11.2 deletion syndrome. This document would help other medical professionals who are less familiar with this genetic syndrome.

In 2012 our new name was launched: **The International 22q11.2 Foundation, Inc.** Our team decided to drop the words “Deletion Syndrome” from the name as we expanded our services to include all individuals and families affected by abnormalities of chromosome 22q11.2. This included those with smaller deletions, those with changes in genes within the region such as TBX1, and those with 22q11.2 duplication syndrome. This was our logo after the name change:



This is the “Call for Abstracts” poster for the 2012 **Biennial International 22q11.2 Conference** in Florida. Our Foundation was proud to be the lead sponsor and convening organization for the family portion of this conference.

Since 1998, medical professionals and researchers, including many of our **Medical Advisory Board** members, have been getting together every 2 years to share their discoveries and experiences. The family meeting portion is a great opportunity for families to find out about the latest research and to support one another.



On January 26, 2012, multiple groups that represent families affected by 22q11.2DS rallied support for newborn screening for 22q11.2 before the US Secretary of Health's Committee on Heritable Disorders and Newborn Screening.

Back Row (Left to Right): Michelle Breedlove-Sells, The Ryan and Jenny Dempster Foundation; Carol Cavana, The International 22q11.2 Foundation; Anne Bassett, MD, The University of Toronto; Sheila Kambin, MD, The International 22q11.2 Foundation; Aoy Mitchell, PhD, Children's Hospital of Wisconsin.

Front Row (Left to Right): John Routes, MD, Children's Hospital of Wisconsin; Donna McDonald-McGinn, MS,CGC, Children's Hospital of Philadelphia; Julie Wootton, UK Max Appeal. Also present but not pictured was Stu Berger, MD, Children's Hospital of Wisconsin.

Walking Down The Memory Lane (p. 3 of 4)

REVIEW **Genetics in Medicine**

Practical guidelines for managing adults with 22q11.2 deletion syndrome

Wai Lun Alan Fung, MD, Scott E. Lacey, MD, Barbara, MSc, Gregory Conboy, PhD,¹ Danielle M. Archbold, MD, Scott E. Lacey, MD, Lisa R. Chow, MD, FRCP(C), Brian Chang, MD, PhD, MBBS, Ercan Ceylanoglu, MD, CGC, Hansa Rajagopal, MD,¹ Leonora Tisherman, MD, PhD, Scott E. Lacey, MD, Scott E. Lacey, MD, PhD, FRCP(C),¹ Anthony J. Lang, MD, FRCP(C),¹ Gabriela Restrepo, MD,¹ Andrew Shaffer, MD, CGC, Candace Schneider, MD, FRCP(C),¹ Anne Sullivan, PhD,¹ Thomas van Amelsvoort, MD, PhD,¹ Donna M. McDonald-McGibin, MD, CGC¹ and Anne S. Bawaft, MD, FRCP(C)^{1,2}

OBJECTIVE: Individuals with 22q11.2 deletion syndrome (22q11.2DS), a neurodevelopmental disorder, have a wide range of clinical manifestations. This review provides practical guidelines for managing adults with 22q11.2DS, focusing on the most common clinical features: cardiac, renal, endocrine, psychiatric, and developmental. The review also discusses the importance of genetic testing and the role of the multidisciplinary team in managing adults with 22q11.2DS. The review is based on a review of the literature and clinical experience.

KEY WORDS: 22q11.2 deletion syndrome, clinical guidelines, multidisciplinary management, genetic testing, psychiatric management, endocrine management, renal management, cardiac management, developmental management, adult management.

INTRODUCTION: Individuals with 22q11.2 deletion syndrome (22q11.2DS) have a wide range of clinical manifestations. The most common clinical features are cardiac, renal, endocrine, psychiatric, and developmental. This review provides practical guidelines for managing adults with 22q11.2DS, focusing on the most common clinical features. The review also discusses the importance of genetic testing and the role of the multidisciplinary team in managing adults with 22q11.2DS. The review is based on a review of the literature and clinical experience.

FOR INDIVIDUALS WITH 22q11.2 DELETION SYNDROME (22q11.2DS) (OMIM 184840/184841), the most common manifestations are cardiac, renal, endocrine, psychiatric, and developmental. This review provides practical guidelines for managing adults with 22q11.2DS, focusing on the most common clinical features. The review also discusses the importance of genetic testing and the role of the multidisciplinary team in managing adults with 22q11.2DS. The review is based on a review of the literature and clinical experience.

TO ADDRESSED the need of individuals presenting with 22q11.2 deletion have prompted demands for information on longer term issues. The existing clinical practice guidelines for 22q11.2DS focused primarily on children/adolescents, and there is a need for information on managing the neurodevelopmental, endocrine, cardiovascular, psychiatric, psychiatric, genetic, counseling, and other issues pertinent to adults with 22q11.2DS. A comprehensive review of the existing literature on 22q11.2DS, complemented by the collective experience of professionals from various disciplines, addressed in using for less than 500 adults with 22q11.2DS.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 462 3601. Email: info@ashg.org. Web: www.ashg.org.

THE FOLLOWING GUIDELINES AND BEST PRACTICES FOR 22q11.2 DELETION SYNDROME: Treatment Clinical Guidelines, Copyright © 2016 American Society of Human Genetics, Inc. All rights reserved. This document is intended for personal use only. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without prior written permission from the American Society of Human Genetics, Inc. For more information, please contact the American Society of Human Genetics, Inc. at 11 Dupont Circle, NW, Washington, DC 20036, USA. Tel: 202 462 3600. Fax: 202 46

In 2015, experts published the first set of clinical guidelines specifically for the care of adults affected by 22q11.2 deletion syndrome. This document would help other medical professionals who are less familiar with this genetic syndrome.

In 2018, we incorporated our motto of **“Detection – Care – Cure”** into our logo:




The International
22q11.2 Foundation Inc.

www.22q.org

In 2021, we revamped our website and got a new logo. In this logo (which we are still using), the **heart** symbolizes the compassion and love we bring to our mission every single day, while our **“q chromosome”** highlights our unparalleled relationship with world experts who tirelessly volunteer on our Executive and Medical Advisory Boards.



International
22q11.2 Foundation



In 2016, we created and produced an educational and inspirational video for newly diagnosed 22q families. This video has been shared through social media and has been watched by thousands of expectant parents throughout the world. Click [here](#) to watch.



Runners, walkers, swimmers, and bike riders and volunteers raised awareness for 22q differences by participating in the 2016 Philadelphia and Denver USA Rock 'n Roll Half Marathon (22k) and Family Fun Run (5k or 10k) series.



Fashion Show in the 22q Family Meeting in Sirmione, Italy, July 2016. Patients, family members, and researchers in the 22q community presented clothes designed by Tessa Koller.



Devin Booker and his family, as well as the Suns organization, hosted the International 22q Foundation “**Meet and Greet**” at the Phoenix Suns game in March 2020.

10th Anniversary

22q and Zoom

Worldwide Awareness Day®

Join us!
May 17th, 2020

DETECT
 We're bringing the
ZOO
 TO YOU!
KNOW
GROW

Different Cities All Day!

[illegible][illegible]

The importance of Prenatal Diagnosis of 22q11.2 Deletion Syndrome (22q11.2DS)

22q11.2DS is a complex genetic condition that affects approximately 1 in 4,000 live births. It is caused by a deletion on the long arm of chromosome 22, specifically at the q11.2 band. This deletion affects several genes, leading to a wide range of clinical manifestations. Prenatal diagnosis is crucial for identifying affected pregnancies, allowing parents to make informed decisions about the management and care of their child.

Why is prenatal diagnosis important?

- 1. Early identification and management:** Identifying 22q11.2DS prenatally allows for early intervention and management of associated health issues, such as cardiac anomalies, feeding difficulties, and developmental delays.
- 2. Informed decision-making:** Prenatal diagnosis provides parents with valuable information about the potential health and developmental outcomes of their child, enabling them to make informed decisions about the pregnancy.
- 3. Genetic counseling:** Prenatal diagnosis is often accompanied by genetic counseling, which helps parents understand the inheritance pattern of 22q11.2DS and the risks of recurrence in future pregnancies.
- 4. Psychological support:** Prenatal diagnosis can provide emotional support and resources for parents, helping them cope with the challenges associated with the condition.
- 5. Research and clinical trials:** Prenatal diagnosis contributes to research efforts aimed at understanding the underlying mechanisms of 22q11.2DS and developing targeted therapies.

How is prenatal diagnosis performed?

Prenatal diagnosis of 22q11.2DS can be performed using several methods, including:

- 1. Chorionic Villus Sampling (CVS):** This procedure involves sampling a small portion of the chorionic villi from the placenta, typically performed between 10 and 13 weeks of pregnancy.
- 2. Amniocentesis:** This procedure involves sampling a small amount of amniotic fluid, typically performed between 15 and 20 weeks of pregnancy.
- 3. Preimplantation Genetic Testing (PGT):** This procedure involves testing embryos created through in vitro fertilization (IVF) for the presence of 22q11.2DS before implantation.
- 4. Non-invasive Prenatal Testing (NIPT):** This emerging method involves analyzing cell-free fetal DNA in the maternal blood, typically performed around 10 weeks of pregnancy.

What are the challenges of prenatal diagnosis?

While prenatal diagnosis of 22q11.2DS is possible, there are several challenges associated with the process:

- 1. Limited availability:** Prenatal diagnosis for 22q11.2DS is not available in all healthcare settings, particularly in rural or underserved areas.
- 2. Cost:** Prenatal diagnosis can be expensive, and insurance coverage may vary, potentially limiting access for some families.
- 3. False results:** There is a risk of false-positive or false-negative results, which can lead to unnecessary anxiety or mismanagement.
- 4. Ethical considerations:** Prenatal diagnosis raises ethical questions about the potential for selective abortion and the impact of genetic testing on fetal rights.
- 5. Psychological burden:** The process of prenatal diagnosis can be emotionally challenging for parents, particularly if the results are positive.



Conclusion

Prenatal diagnosis of 22q11.2DS is a critical tool for identifying affected pregnancies and providing parents with the information needed to make informed decisions. While there are challenges associated with the process, the benefits of early identification and management outweigh the risks. Continued research and improved diagnostic techniques will further enhance the accuracy and accessibility of prenatal diagnosis for 22q11.2DS.

[illegible][illegible]

A tall, illuminated tower with a red and white design, resembling the CN Tower, stands prominently against a dark night sky. The tower is surrounded by city lights and trees in the foreground.

To help families understand their conditions and navigate through medical appointments, we launched the [Health Conditions Explained](#) section on our website in 2022. As of February 2025, we have published the Palate Series, the Heart Series, the Dental Series, the Gastrointestinal Series, the Mental Health Series, the Speech Series, the Immune System Series, and the Glossary.



5

A Little History on 22q11.2 Deletion Syndrome

Have you ever wondered how far we have come in discovering knowledge around 22q11.2 deletion syndrome and building our support community?

Recently, the *Journal of Medical Genetics* (JMG) published the [Six at Sixty](#) series to reflect on key achievements and highlight some of the most influential research in the past 60 years. Professor **Peter Scambler**, from University College London in the UK, a founder and first chair of the [22q11.2 Society](#) and a member of our Foundation's [Medical Advisory Board](#), was invited to write a [commentary on 22q11.2DS](#). He wrote about the early years when his team (and a separate team involving our founding board member, Professor **Donna McDonald-McGinn** from the Children's Hospital of Philadelphia in the USA) published landmark studies on the clinical features associated with 22q11.2DS. Be sure to check out his commentary to find out more. You can also read about the start of the international conferences as well as the awareness and support initiatives.



Professor Peter Scambler

- [Six at Sixty. 'Have you tested for 22q?'](#) – Commentary (2025) by Peter Scambler; part of the [Six at Sixty](#) series and the [February 2025 edition of JMG](#)
- [Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study](#) – Research report (1997) by a team led by Peter Scambler
- [The 22q11.2 Deletion: Screening, Diagnostic Workup, and Outcome of Results; Report on 181 Patients](#) – Research report (1997) led by Donna McDonald-McGinn
- [Same Name Campaign](#) – Initiated by Donna McDonald-McGinn and our Foundation, also part of the website of the Dalglish Family 22q Clinic, Toronto, Canada; includes historical information on 22q11.2DS

Adult Congenital Heart Disease (ACHD): A Walk Down Memory Lane

Decades ago, before the 1960s, the vast majority of babies (with or without 22q differences) who were born with major congenital heart diseases (CHD) would not have survived. Over the years, heart surgeries for babies and children with CHD have become more and more successful. By the year 2000, over 90% of children with CHD survived to adulthood.

About 1 in 4 individuals with a 22q11.2 deletion (22q) is born with a major CHD. Although many are initially repaired during childhood, the heart needs to be checked by specialists throughout life. Staff members at the Dalglish Family 22q Clinic in Toronto, Canada, work closely with the experts at the Toronto ACHD (Adult CHD) program as they care for adults with 22q who have major CHD.

Recently, Dr. Jack Colman, a cardiologist who recently retired from the ACHD program, and his colleagues published a paper entitled [Toronto ACHD program: A 65 year legacy](#). It describes the evolution of this trailblazing program at the Toronto General Hospital. The Program's journey began in 1959 with the early surgeries performed at the

Hospital for Sick Children, then went through multiple stages over the years, all the while making pioneering advances to improve and extend the lives of adults with CHD.

The article notes many innovative aspects of this special program – including the Dalglish Family 22q Clinic led by **Dr. Anne Bassett**, the Medical Director of our Foundation. The Toronto ACHD group currently has over 12,000 active patients with all sorts of CHD conditions, and provides training and guidance to cardiologists and related specialist clinicians all over the world.

We invite you to take a trip down memory lane in Dr. Colman's article to see how far we have come on the care of ACHD. For information on CHD associated with 22q, please see the Heart Series in the [Health Conditions Explained](#) section of the website of our Foundation.

[Toronto ACHD program: A 65 year legacy](#)

Alonso-Gonzalez R., Benson L., Colman J.M., Harris L., Heggie J., Oechslin E., Silversides C.K., Williams W.G. *International Journal of Cardiology Congenital Heart Disease*, Volume 19, March 2025

22q Differences and Inflammatory Profiles

[Differential inflammatory profiles in carriers of reciprocal 22q11.2 copy number variants.](#)

O'Hara KP, Amir CM, Chiem E, Schleifer CH, Grigoryan V, Kushan-Wells L, Chiang JJ, Cole S, Irwin MR, Bearden CE.

Psychoneuroendocrinology. 2024 Nov;169:107135. doi: 10.1016/j.psyneuen.2024.107135. Epub 2024 Jul 20. PMID: 39116521.

Background Information

Inflammation is a normal part of our body's immune response to injuries and pathogens. The acute symptoms (pain, redness, swelling, and heat) help clear away the invaders and protect the host. However, inflammation can be harmful if it goes out of control, continues for too long, or attacks healthy tissues.

When immune cells need help battling pathogens, they release signaling molecules called **cytokines**. There are many different cytokines. The ones that promote inflammation include:

- Interleukin-6 (IL-6)
- Interleukin-8 (IL-8)
- Tumor Necrosis Factor α (TNF- α)
- Interferon- γ (IFN- γ)

These cytokines can go into the brain to activate the immune cells that protect the brain from infection and injury. However, immune activation and inflammation in the brain for a long time can lead to changes in mood, learning/thinking, and behavior.

Interleukin-8 (IL-8) is a cytokine that attracts other immune system cells to clear invading pathogens and protects the host. Higher levels of IL-8 have previously been associated with mental health conditions such as bipolar disorder, schizophrenia, and generalized anxiety disorder.

Psychosis is a symptom in which the person has difficulty telling apart what is real and what is not. They may hear voices or see things that are not there. They may believe that someone is out to harm them when this is not the case. Schizophrenia is a treatable **psychotic disorder** that is associated with **22q11.2DS**.

For more information on immunological and mental health conditions that are associated with **22q11.2DS** and **22q11.2DupS**, please check out our **Health Conditions Explained** webpage.

In this study, researchers checked to see if the blood sample levels of **cytokines involved in inflammation** are related to **mental health problems** and **sleep interruptions** in people with **22q11.2DS** and **22q11.2DupS**.

Study location/participants

- University of California at Los Angeles (UCLA)
- Participants (8 to 49 years) fit into 3 groups:
 - 45 with confirmed **22q11.2DS**
 - 29 with confirmed **22q11.2DupS**
 - 92 typically developed (TD) individuals with similar age and social characteristics as the test groups

Findings

- \uparrow Body mass index was associated with \uparrow levels of pro-inflammatory cytokines in all 3 groups of participants
- **22q11.2DupS** carriers had **higher IL-8 levels** compared to TD individuals, and to a lesser extent, **22q11.2DS** carriers
- There were no significant differences between the 3 groups in the levels of other pro-inflammatory cytokines.
- **22q11.2DS carriers with psychosis risk symptoms** had **higher IL-8 levels** compared to 22q11.2DS carriers with no psychosis risk symptoms.
- 22q11.2DS carriers with no psychosis risk symptoms had levels of IL-8 that were similar to those of TD individuals
- There were no significant relationships between sleep and pro-inflammatory cytokine levels.

Main message

- IL-8-related inflammatory activities may play a role in increased psychosis risk in individuals with **22q11.2DS**.
- \uparrow IL-8 in **22q11.2DupS** carriers may indicate immune activities that are different from those resulting in \uparrow IL-8 in **22q11.2DS** carriers. In other words, **22q11.2 deletions** and **duplications** may impact IL-8-related processes differently.
- More research is needed to understand the roles of IL-8 in 22q11.2 differences and in psychosis risk.

Immune System Series Now Available

In December, we presented 4 topics from the Immune System Series of the “[Health Conditions Explained](#)” section of our website. We have now generated info sheets for 4 more topics to complete the series. Special thanks to Dr. Kathleen Sullivan, Immunologist at the Children's Hospital of Philadelphia and Joanne Loo, Programmatic and Educational Tool Developer of our Foundation.

Published in December, 2024

- [The Immune System](#)
- [Vaccination](#)
- [Immune Deficiency Related to T Cells](#)
- [Immune Deficiency Related to B Cells](#)

Published in February, 2025

- [Autoimmune Disorders](#)
- [Allergies and Asthma](#)
- [Immune System Issues in 22q11.2DS](#)
- [Immune System Issues in 22q11.2DupS](#)

Be sure to check out all the topics in the “[Health Conditions Explained](#)” section of our website!

- Heart Series
- Dental Series
- Palate Series
- Mental Health Series
- Speech Series
- 22q Glossary (3rd ed.)
- Gastrointestinal (GI) Series
- Immune System Series

Disclaimer: This information is brought to you by the International 22q11.2 Foundation for educational purposes only. It is not intended to be taken as medical advice. If you have concerns, please talk to your healthcare provider.

Clinical Recommendations for 22q11.2DS Now Available in 4 Languages

A number of individuals as well as members of the [22q11.2 Society](#) have been working hard on the translation of the clinical recommendation documents. Since we sent you our December newsletter, the French and Chinese translations of the pediatric clinical recommendations have become available. We thank Nicole Philip, Bekah Wang, Huiyun Wang, and Joanne Loo for their hard work and dedication.

The clinical recommendations for both children and adults are now available in 4 languages. The links to the original and all translations of the clinical recommendation documents will be posted on the [22q11.2 Society website](#) as they become available.

Clinical Recommendations 2023

Updated clinical practice recommendations for managing **children** with 22q11.2 deletion syndrome

- [English](#) (Original)
- [Spanish / Español](#)
- [French / Français](#) [NEW]
- [Simplified Chinese / 简体中文](#) [NEW]

Updated clinical practice recommendations for managing **adults** with 22q11.2 deletion syndrome

- [English](#) (Original)
- [Spanish / Español](#)
- [French / Français](#)
- [Traditional Chinese / 繁體中文](#)


Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions

- [English](#) (Original)


19th Annual Faces of Sunshine Calendar



Cover



January



February




March



April



May




June




July




August



September




October



November



December



22q International 22q11.2 Foundation

Many thanks to all who submitted photos for the 2025 calendar. The names of the featured individuals have now been posted on the [Calendar Campaign](#) webpage of the Foundation.

This calendar is a great way to show your 22q pride. We hope you enjoy the calendar as well as all of the beautiful faces of sunshine throughout 2025!

Calendars may be [ordered via our website](#). All proceeds benefit the work of the International 22q11.2 Foundation, Inc.

Thank you for your support!

January – **Gabriel E** from Erwin, Tennessee

February – **Penelope A** from Bronx, New York

March – **Sadie W** from Binghamton, New York

April – **Isabel S** from West Fulton, New York

May – **Hannah C** from Sparta, Kentucky

June – **Jaxson P** from Hudson, North Carolina

July – **Collins H** from Brecksville, Ohio

August – **Gavin R** from Martinez, California

September – **Landon V** from Pylesville, Maryland

October – **Gabriel “Gabe” D** from Lexington, South Carolina

November – **Cory, Collin & Trevor** from Alberta, Canada

December – **Sanibel A** from Windsor, Colorado

...and the 2025 Cover Goes to:

Aideen U from Maple Shade, New Jersey

Did You Miss Our No Show Valentine's Ball?

It's not too late!

Instead of attending a ball in person, we invite you to make a donation to the International 22q11.2 Foundation. Your gift will support our work and help families with 22q differences.

Thank you!



you're invited! **2025**

No-Show Valentine's Ball

at your home at any time

It's a fabulous affair you will never attend. We will proudly present not a single speech, no entertainment, no cocktail hour, no valet parking, no need to be there.

Instead... WE CORDIALLY INVITE YOU TO JOIN US IN SPIRIT

By making a contribution to The International 22q11.2 Foundation.

Visit our website at www.22q.org or click on No Show Valentine's Ball for more info.

#22qawareness | 22q.org | @22qFoundation

Donation Menu

- Table of 10 friends I do not have to persuade to attend!
- Providing this gift in lieu of his & her new outfits!
- Please accept this donation in place of raffle tickets!
- It is not that I don't enjoy eating out!
- Saving on a Valentine's Day babysitter and Uber.
- Home before midnight – priceless!
- Cozy by the fire! – I'll take that any day of the week!
- Helping families in need!

\$5222.00 USD
\$2222.00 USD
\$1222.00 USD
\$522.00 USD
\$222.00 USD
\$122.00 USD
\$52.00 USD
\$22.00 USD

2025 Lighting Request Letter Now Available

Let's raise awareness for 22q differences!

We invite you and your town to join an international movement of lighting up buildings and monuments in red on the evening of **November 22nd (22/11; or 11/22 in North America)** as a play on the name of the 22q11.2 deletion and duplication syndromes.

Some buildings may already have an online system for submitting lighting requests. If you do not find an online form, you can use a letter from our Foundation to **request red lighting on Saturday, November 22nd, 2025**. Click on image of the letter on the right to access the pdf file of the letter. **Download** the file to your own drive or cloud. Fill in the name of the building and the city or town, then email or mail the letter to the government or organization that manages the building.

On the night of **November 22nd, 2025**, take pictures of yourself with the illuminated building and share them on social media.

Together, we will light up the night for 22q!

Light up the Night for 22q11.2!

Greetings from the International 22q11.2 Foundation, Inc.

November 18 22q11.2 Awareness Month

22q11.2 deletion and duplication syndromes are underrecognized genetic conditions that affect about 1 in 1000 pregnancies and 1 in 2000 live births. These conditions occur when a very small piece of chromosome 22 is missing or extra, resulting in the loss or gain of about 50 genes that help direct how the body is formed and functions. The most common associated features include birth defects (such as heart, palate and kidney problems), multiple medical conditions (including low calcium, difficulty fighting infection, feeding and swallowing differences, and seizures), developmental delay, learning differences, and behavioral health problems, such as ADHD, anxiety, autism, and psychiatric illness. Many individuals require care from multiple specialists across the lifespan, but there is also very broad variability.

Most deletions and duplications are the same size with a subset being a bit smaller. All can occur randomly for the first time in the person who has the chromosome difference and nothing that the parents did or did not do cause it to occur. However, once a person has the deletion or duplication there is a 50% chance of passing it on in every pregnancy.

Chromosome 22q11.2 differences are the most common chromosomal conditions after Down Syndrome. However, most people have never heard of chromosome 22; and some people with these differences spend years searching for a diagnosis. To increase public awareness, in 2018, La Asociación Síndrome 22q11 in Spain launched an awareness campaign entitled "Luces por el 22q" (Lighting the Night for 22q). Buildings and monuments were illuminated in red on November 22 (22/11 in many parts of the world but 11/22 in North America) as a play on the name of the chromosome difference. Cities in Belgium, Poland, Canada, Finland, Germany, and the USA soon followed. At the bottom of this page are example photos from November 22 of previous years, where buildings were lit up in red to support 22q awareness. Please consider joining this international endeavor so that no child or adult struggles to find a diagnosis in a timely fashion. Therefore, we respectfully request that...

November 22, 2025 to raise awareness for chromosome 22q11.2 deletion and duplication syndromes. Questions? Please contact the International 22q11.2 Foundation, Inc. at 001.877.739.1849 or info@22q.org

Thank you in advance for your kind consideration.

The International 22q11.2 Foundation, Inc.
PO Box 532
Madison, NJ 07747, USA
www.22q.org

22q
International
22q11.2 Foundation

Lighting Request Letter



22q at the Zoo May 18th, 2025

22q at the Zoo is an annual event that happens at zoos and other fun places all around the world, giving families, friends and professionals a chance to socialize, network and raise public awareness of 22q11.2 differences.

In this event developed by the International 22q11.2 Foundation, volunteers spread awareness by handing out information about chromosome 22q differences. Participants are recognizable by wearing official **“22q at the Zoo” red T-shirts** and **“Ask Me About 22q”** buttons.

Visit our Foundation’s **22q at the Zoo** webpage to check for an event in your area. The webpage will be updated on an ongoing basis as more volunteers step up to host the event.

If there are no 22q at the Zoo events in your area, you can host one! Please visit the **Host a 22q at the Zoo Event** section on our website for more information. We even have an event planner letter ready for you! No zoo? No problem. Consider gathering at a park, a farm, or even an aquarium. If you have any questions, please email us at **info@22q.org**.

**See you at the zoo on
Sunday May 18th!**



Upcoming Symposiums / Meetings / Gala



Save the date for our 22q Symposium

Come learn from experts about 22q11.2 Deletion Syndrome (aka DiGeorge Syndrome) the second most common chromosomal defect after Down Syndrome

When: March 29th, 2025
Where: Memorial Regional Conference Center
RSVP: floridaconquers22q@gmail.com

Limited seats available

Donations are welcomed to support similar events in the future

Joe DiMaggio Children's Hospital
22Q Multidisciplinary Program

The World View on 22q

an International Scientific and Family meeting

Save the Date!



 **Scientific Symposium**
September 4, 2025

Family Meeting
September 5-6, 2025

 **The Children's Hospital of Philadelphia**
Philadelphia, Pennsylvania, USA

 **Sponsored by**
The International 22q11.2 Foundation
and The 22q and You Center
at the Children's Hospital of Philadelphia



AROUND THE WORLD WITH 
CELEBRATING 22 YEARS OF THE
INTERNATIONAL 22q11.2 FOUNDATION





Save The Date
for a
Black Tie Gala

06 | SEPTEMBER | 2025
PHILADELPHIA, PENNSYLVANIA

Florida Conquers 22q

March 29, 2025 (Saturday)
Joe DiMaggio Children's Hospital/
Memorial Regional Conference
Center

[Registration Link](#)

The World View on 22q

Scientific symposium: Sept 4, 2025
Family Meeting: Sept 5-6, 2025
Philadelphia, Pennsylvania
More information to come.

Around the World with 22q

September 6, 2025
Philadelphia, Pennsylvania
More information to come.

Donate Now

Our mission: to improve the quality of life for individuals affected by chromosome 22q11.2 differences through family and professional partnerships.



What would we do with the funds:

- Support Research
- Support family conferences
- Support awareness
- Support Newborn Screening
- Support and raise awareness for 22q!

Your support makes a difference!

There are so many options for **Team 22q Fundraising**! Take part in one of the Foundation's event or create your own.

Please visit the **Donate** page on our website for information on donating online, by mail, or via other methods.

Please also **Shop** on our webstore.

For more information, please visit our website at **www.22q.org** or email us at **info@22q.org**.

Team 22q Fundraising

- **Tell 22 Friends** about 22q
- Become a **monthly donor**
- Be a 22q Citizen Journalist and share your event on social media!
- Plan a **22q at the Zoo** event
- Plan a **22K for 22q** event
- (It can also be 2.2K!)
- Create Your Own Event or Fundraiser Contact us at **info@22q.org**

Thank you!

Connect With Us



The mission of the **International 22q11.2 Foundation** is to improve the quality of life for individuals affected by chromosome 22q11.2 differences through family and professional partnerships.

This information is brought to you by the Foundation for educational purposes only. It is not intended to be taken as medical advice. If you have concerns, please talk to your healthcare provider.

Copyright © 2025 – The International 22q11.2 Foundation, Inc.

International 22q11.2 Foundation, Inc.

PO Box 532, Matawan, NJ 07747

www.22q.org (877) 739-1849 **info@22q.org**